Evidence map›Paper›PMID 40597839›Full record

ArticleBMC cancer2025

Development and validation of a small-sample machine learning model to predict 5-year overall survival in patients with hepatocellular carcinoma.

Tingting Jiang, Xingyu Liu, Wencan He, Hepei Li, Xiang Yan, Qian Yu, Shanjun Mao

Abstract readValidation Study
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tingting JiangDivision of Head & Neck Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, 610041, China.
Xingyu LiuDepartment of Statistics and Data Science, Hunan University, Changsha, Hunan Province, 410000, China.
Wencan HeSchool of Life Sciences, Central South University, Changsha, Hunan Province, 410078, China.
Hepei LiDivision of Head & Neck Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, 610041, China.
Xiang YanInstituto De Micro Y Nanotecnología, IMN-CNM, CSIC (CEI UAM + CSIC), Isaac Newton, 8, E-28706 Tres Cantos, Madrid, Spain.
Qian YuPrecision Medicine Institute, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong Province, 510080, China. yuqian27@mail.sysu.edu.cn.
Shanjun MaoDepartment of Statistics and Data Science, Hunan University, Changsha, Hunan Province, 410000, China. shjmao@hnu.edu.cn.

Funding

Excellent Young Scholar Project of Hunan Provincial Education Department 23B0033National Natural Science Foundation of China 12401381National Natural Science Foundation of China 82201339Natural Science Foundation of Changsha kq2402048Natural Science Foundations of Hunan Province 2025JJ60043
6 · The paper itself

Abstract

backgroundEarly-onset hepatocellular carcinoma (HCC) is insidious, with characteristics of easy metastasis, high recurrence rate, and significant mortality. To address the substantial time and resource demands associated with HCC prognostic prediction, we extract meaningful insights from limited small-sample data to develop and validate a prediction model for HCC 5-year overall survival (OS) by machine learning (ML).

methods76 newly diagnosed patients with HCC were eventually enrolled between September 2018 and July 2019. The follow-up time was 1-67 months. Patients who survived for 5 years after the first surgery, were divided into a surviving group (n = 34) and a nonsurviving group (n = 42). Pathological data and related survival factors of patients were collected before treatment. The final subset of features was filtered. Prediction models for 5-year OS in patients with HCC were established by logistic regression (LR), support vector machine (SVM), decision tree classification (DTC), random forests (RF), and extreme gradient Boosting (XGBoost), respectively. Additionally, the optimal model was established after rigorous validation. The models were evaluated by values of specificity, F1 score, recall, accuracy and area under the receiver operating characteristic curve (AUC-ROC). The decision curve analysis (DCA) method was assessed the evaluation. Finally, internal and external validations were performed to further validate model' robustness.

resultsThe significant variable set, which included 22 variables, was screened. Ranking the importance of variables, the top 22 characteristic variables were as follows: the maximum diameter, presence or absence of distant metastasis, CNLC stage, ALB, age, RBC, the large size CTC, total bilirubin (TBIL), PD-L1 (-) CTC, ≥ Pentaploid CTC, AFP, vascular cancer thrombus and satellite nodules, WBC, CTC, BCLC stage, multiple nodules, AST, PD-L1 (-) CTC-WBC cluster, Triploid CTC, LYM, PD-L1 (-) CEC-WBC cluster and degree of cirrhosis. The AUC-ROC values for predicting the 5-year OS rate of HCC patients by the logistic regression, SVM, DTC, RF, and XGBoost models were 0.737, 0.971, 0.657, 0.741, and 0.703, respectively. Among them, the SVM model had the best performance (Accuracy = 0.987, F1 score = 0.988, Recall value = 1.000). The SVM algorithm demonstrated superior performance and stability in the internal and external validations of the model.

conclusionThe SVM model could predict the 5-year OS in HCC with good recognition ability and achieves significantly greater accuracy compared to traditional models. Diagnosis and treatment could be utilized to intervene in the risk factors in this model, thereby improving patient prognosis.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsMachine LearningAdultAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisROC CurveCECClinicopathological characteristicCTCHCCHematological biomarkerOSSmall-sample ML

Identifiers

PMID40597839
PMCPMC12211751

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.